These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 3088511)

  • 1. [Treatment of extra-puerperal galactorrhea with the MAO-B inhibitor selegiline].
    Sas M; Godó G; Koleszár G
    Orv Hetil; 1986 Jun; 127(25):1507-8, 1511. PubMed ID: 3088511
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical efficacy of deprenyl, a specific inhibitor of MAOB.
    Psychopharmacol Bull; 1983; 19(3):328-42. PubMed ID: 6314420
    [No Abstract]   [Full Text] [Related]  

  • 3. R-(-)-deprenyl as a possible protective agent in Parkinson's disease.
    Tetrud JW; Langston JW
    J Neural Transm Suppl; 1987; 25():69-79. PubMed ID: 3123606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Use of iumeks in the combined therapy of parkinsonism patients ].
    Man'kovskiĭ NB; Karaban' IN; Mialovitskaia EA
    Vrach Delo; 1987 Aug; (8):100-2. PubMed ID: 3120415
    [No Abstract]   [Full Text] [Related]  

  • 5. Neurochemical insights into monoamine oxidase inhibitors, with special reference to deprenyl (selegiline).
    Riederer P; Jellinger K
    Acta Neurol Scand Suppl; 1983; 95():43-55. PubMed ID: 6145282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.
    Henchcliffe C; Schumacher HC; Burgut FT
    Expert Rev Neurother; 2005 Nov; 5(6):811-21. PubMed ID: 16274338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selegiline HC1: Selective MAO-type B inhibitor.
    Koller WC; Giron LT
    Neurology; 1990 Oct; 40(10 Suppl 3):suppl 58-60. PubMed ID: 2120616
    [No Abstract]   [Full Text] [Related]  

  • 8. MAO-B inhibitors for the treatment of Parkinson's disease.
    Mov Disord; 2002; 17 Suppl 4():S38-44. PubMed ID: 12211138
    [No Abstract]   [Full Text] [Related]  

  • 9. Monamine oxidase inhibitors: current and emerging agents for Parkinson disease.
    Fernandez HH; Chen JJ
    Clin Neuropharmacol; 2007; 30(3):150-68. PubMed ID: 17545750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deprenyl in the treatment of Parkinson's disease. A specific type B monoamine oxidase inhibitor.
    Lieberman AN; Gopinathan G; Neophytides A; Hiesiger E; Nelson J; Walker R; Goodgold A
    N Y State J Med; 1984 Jan; 84(1):13-6. PubMed ID: 6422358
    [No Abstract]   [Full Text] [Related]  

  • 11. Studies of selective and reversible monoamine oxidase inhibitors.
    Mann JJ; Aarons SF; Frances AJ; Brown RD
    J Clin Psychiatry; 1984 Jul; 45(7 Pt 2):62-6. PubMed ID: 6429130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of monoamine oxidase type A, but not type B, is an effective means of inducing anticonvulsant activity in the kindling model of epilepsy.
    Löscher W; Lehmann H; Teschendorf HJ; Traut M; Gross G
    J Pharmacol Exp Ther; 1999 Mar; 288(3):984-92. PubMed ID: 10027835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K
    Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Big first scored with nerve diseases.
    Lewin R
    Science; 1989 Aug; 245(4917):467-8. PubMed ID: 2502841
    [No Abstract]   [Full Text] [Related]  

  • 15. Reversal of stress-induced deficit in aggression by monoamine oxidase inhibitors.
    Ossowska G; Klenk-Majewska B; Danilczuk Z; Wróbel A; Zebrowska-Lupina I
    Pol J Pharmacol; 1999; 51(5):391-7. PubMed ID: 10817539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selegiline in Parkinson's disease.
    Teräväinen H
    Acta Neurol Scand; 1990 Apr; 81(4):333-6. PubMed ID: 2113756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relative efficacy of l-deprenyl, a selective monoamine oxidase type B inhibitor, in endogenous and nonendogenous depression.
    Mann JJ; Frances A; Kaplan RD; Kocsis J; Peselow ED; Gershon S
    J Clin Psychopharmacol; 1982 Feb; 2(1):54-7. PubMed ID: 6802883
    [No Abstract]   [Full Text] [Related]  

  • 18. [Experience using selective monoamine oxidase inhibitors in treating parkinsonism patients].
    Stoliarova LG; Kadykov AS; Shvedkov VV; Shakhparonova NV
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1988; 88(12):11-3. PubMed ID: 3149842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Therapeutic usefulness of bromoergocriptine (CB-154 Sandoz) in patients with galactorrhea (author's transl)].
    González Colindres JA; Canales ES; Levinson G; Zárate A; Sorta J
    Rev Invest Clin; 1975; 27(2):135-8. PubMed ID: 1237173
    [No Abstract]   [Full Text] [Related]  

  • 20. Monoamine oxidase-B inhibition in the treatment of Parkinson's disease.
    Fernandez HH; Chen JJ
    Pharmacotherapy; 2007 Dec; 27(12 Pt 2):174S-185S. PubMed ID: 18041937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.